GLP-1 drugs like Ozempic and Wegovy are cutting obesity rates for the first time in a generation. Black Americans carry the highest burden of obesity and diabetes in the country. And yet, we are being prescribed these drugs at the lowest rates. The numbers make the case. The system is making the choice.
GLP-1 drugs — Ozempic, Wegovy, Zepbound, Mounjaro — are the most significant advance in obesity medicine in a generation. They cut body weight by 15–20% in clinical trials. Moreover, Gallup confirmed in 2025 that U.S. obesity rates dropped for the first time in years, driven directly by rising GLP-1 use. However, Black Americans — who have the highest rates of obesity and diabetes in the country — are 19% less likely to be prescribed these drugs than white patients. That gap is not an accident. It is the product of cost barriers, insurance exclusions, and the same racial calculus that has defined American medicine for two centuries.
- GLP-1 drugs drove the first measurable U.S. obesity decline in years — from 39.9% in 2022 to 37.0% in 2025, per Gallup
- Black Americans are 19% less likely to receive a GLP-1 prescription than white patients, despite higher obesity and diabetes rates
- White patients have a nearly 40% lower diabetes prevalence than Black patients — yet receive GLP-1 prescriptions at roughly four times the rate
- Wegovy launched at over $1,300 per month; most state Medicaid plans exclude GLP-1 drugs for weight-loss use
- Louisiana — where Black residents make up 33% of the population — has a 40%+ obesity rate, among the highest nationally
- The TrumpRx pricing deal brought GLP-1 costs to approximately $245/month, with a $50 Medicare copay bridge launching July 2026
- Black men are among the racial groups least likely to receive GLP-1 prescriptions, per the Institute for Clinical and Economic Review
Every few years, medicine produces something that genuinely changes the terms of the conversation. Not a refinement. Not an incremental improvement. A fundamental shift in what is medically possible. GLP-1 drugs represent that kind of moment — and Black America is being systematically excluded from it.
Ozempic. Wegovy. Zepbound. Mounjaro. You have heard the names. You have seen the headlines and the before-and-after photos. Consequently, the cultural conversation has shifted from “miracle drug” to “Hollywood drug.” Neither framing captures what the data actually shows.
According to the Gallup National Health and Well-Being Index, published in October 2025, U.S. obesity rates dropped from 39.9% in 2022 to 37.0% in 2025. That represents approximately 7.6 million fewer obese adults. Furthermore, clinical trials have demonstrated that GLP-1 medications produce 15–20% average weight loss while also reducing cardiovascular risk, protecting kidney function, and lowering blood sugar. In January 2025, the FDA expanded Ozempic’s approval to cover chronic kidney disease risk reduction in adults with type 2 diabetes.
This is real. This matters. And yet, Black America is being left out of it — at precisely the moment when these drugs could save the most lives in our communities.
The Prescription Gap That Nobody Is Talking About
Black Patients Need These Drugs Most — And Receive Them Least
Start with the baseline facts. Black Americans have higher rates of obesity than white Americans. Additionally, we have higher rates of type 2 diabetes, hypertension, heart disease, and chronic kidney disease — all conditions that GLP-1 drugs are now approved or being studied to treat.
White patients have a nearly 40% lower prevalence of diabetes than Black patients. That is not a small gap. Furthermore, despite carrying that heavier disease burden, white patients are approximately four times more likely to receive a semaglutide prescription than Black patients, according to research cited by Healthline.
A peer-reviewed cohort analysis published in 2024 confirmed the pattern across multiple GLP-1 drugs. Compared to white patients, Black patients showed significantly lower odds of receiving semaglutide, tirzepatide, and dulaglutide prescriptions. The researchers concluded that white patients were consistently more likely to receive these medications than all non-white racial and ethnic groups combined.
The Numbers Tell the Full Story
This is not a data anomaly. It is a documented pattern. Moreover, patterns in medicine that consistently break along racial lines have a name. This one is called a disparity. Disparities, when left unaddressed, compound into decades of preventable illness and preventable death.
“The inequities of access to these medications depend on prior factors — insurance status, access to medical care. If a certain group is not even eligible for GLP-1 drugs, then right out of the gate, they are at a disadvantage.”
— Dr. Reddy, via HealthlineWhy the Gap Exists — And Why Cost Is Only Part of the Answer
The Price Barrier Is Real and Documented
The most direct explanation for the disparity is cost. Wegovy launched at over $1,300 per month. Even after the Trump administration’s TrumpRx pricing agreement — which brought the major GLP-1 drugs to approximately $245 per month for self-pay patients — the financial barrier remains severe for millions of Americans.
Under TrumpRx, Ozempic, Wegovy, Mounjaro, and Zepbound are priced at roughly $245/month. A $50/month Medicare copay bridge launches July 2026. Cash-pay options range from approximately $150 to $450/month. However, only 19% of firms with 200 or more workers include GLP-1 coverage for weight loss in their largest health plan. California’s Medi-Cal ended GLP-1 weight-loss coverage effective January 1, 2026. Most state Medicaid programs follow similar restrictions.
Black Americans are more likely to be uninsured or underinsured than white Americans. They are more likely to rely on Medicaid, which in most states does not cover GLP-1 drugs for weight loss specifically. Furthermore, they are less likely to work at the large employers whose benefits packages include this coverage. Consequently, the very structure of how these drugs are distributed systematically excludes the communities that need them most.
According to The Health Management Academy’s 2026 analysis, states with the highest income burden for GLP-1 costs also have the highest obesity rates — notably Mississippi, West Virginia, and Louisiana, where rates exceed 40%. If you are Black and living in Louisiana and need Ozempic, the barriers stack on top of each other at every level simultaneously.
Bias in the Exam Room Compounds the Structural Problem
However, cost does not explain everything. Studies have found that even among patients with identical insurance coverage, Black patients receive GLP-1 prescriptions at lower rates than white patients. Something additional is operating in the exam room.
Research has documented that physicians are less likely to recommend weight-loss interventions — including medication — to Black patients compared to white patients with the same clinical profile. Additionally, Black Americans are less likely to have a consistent primary care physician. Without that relationship, a GLP-1 prescription becomes nearly impossible to obtain, regardless of insurance status.
Furthermore, there is the question of trust. Black Americans have documented, historically justified reasons to approach medical recommendations with caution. That history does not disappear in the exam room. Instead, it shapes the conversation between patient and physician in ways that affect what gets recommended and what gets accepted. Therefore, addressing the disparity requires more than lowering drug prices. It requires rebuilding a relationship between Black patients and a medical system that has not always earned their trust.
What GLP-1 Drugs Actually Do — And What Black Communities Are Missing
This Goes Far Beyond Weight Loss
The popular conversation about GLP-1 drugs has been dominated by celebrity users and aesthetic results. As a result, the full medical picture has been obscured. These medications are not simply diet pills. They are metabolic interventions with documented benefits across multiple organ systems.
Beyond weight loss, GLP-1 drugs are now FDA-approved for reducing cardiovascular death risk, protecting kidney function in diabetic patients, and managing blood sugar in type 2 diabetes. Additionally, ongoing studies are examining potential benefits for Alzheimer’s disease, addiction disorders, and obstructive sleep apnea.
For Black Americans — who have elevated rates of heart disease, kidney disease, type 2 diabetes, and hypertension — the potential benefit is not theoretical. It is survival. Consequently, the question of who receives these drugs is not a question about weight or appearance. It is a question about who gets to live longer.
The Diabetes Connection Is the Most Urgent Issue
Black Americans are diagnosed with type 2 diabetes at nearly double the rate of white Americans. GLP-1 drugs were originally developed specifically to treat type 2 diabetes. Moreover, Ozempic has demonstrated dramatic reductions in cardiovascular events among diabetic patients — the exact population where Black Americans are most overrepresented.
According to the CDC’s 2024 data, Black non-Hispanic adults with diagnosed diabetes used GLP-1 injectables at 26.5% — nearly the same rate as white non-Hispanic adults at 26.2%. That near-parity, however, applies only to people who are already inside the medical system receiving diabetes treatment. The larger problem is that Black Americans are less likely to reach that point of care in the first place. Without consistent primary care access, there is no prescription. Without a prescription, there is no treatment. Without treatment, the disease progresses.
The System Is Making a Choice — And That Choice Has Consequences
There is a tendency, when discussing health disparities, to reach for the language of complexity. It is complicated. There are many factors. In practice, however, that language is often used to avoid a simpler and harder statement that the data fully supports.
The statement is this: American healthcare has consistently distributed medical innovation in ways that benefit white patients before Black patients. Moreover, this is not speculation. It is the documented pattern of insulin distribution in the early 20th century, statin distribution in the late 20th century, and COVID-19 vaccine distribution in 2021. Now it is the pattern of GLP-1 distribution in 2026.
Each time, the primary explanation offered is cost. Each time, that explanation is partly accurate and substantially insufficient. Furthermore, each time, the communities carrying the heaviest disease burden are the last to receive the treatment that addresses it. As the Los Angeles Times concluded in April 2024: these miracle drugs could have reduced health disparities. Instead, they made them worse.
“Miracle weight-loss drugs could have reduced health disparities. Instead, they got worse.”
— Los Angeles Times, April 2024What Needs to Change — And What You Can Do Right Now
The Policy Fixes That Would Actually Move the Needle
The TrumpRx pricing deal is a meaningful step. Nevertheless, it does not resolve the Medicaid gap, the employer coverage gap, or the primary care access gap that drive the disparity for the patients who need these drugs most.
Specifically, what would move the needle: universal Medicaid coverage for GLP-1 drugs for all clinically eligible patients, regardless of whether the primary indication is diabetes or obesity. Beyond that, sustained investment in community health centers in Black neighborhoods would build the primary care infrastructure needed to connect patients with prescribers. Additionally, physician training on implicit bias in prescribing decisions would address what happens inside the exam room once patients do arrive.
What You Can Do in the Exam Room Today
If You or Someone You Love Needs a GLP-1 Drug — Here Is How to Fight for Access
- Ask directly. Ask your physician whether you qualify for a GLP-1 medication. If your BMI is 27 or higher with a related condition — diabetes, hypertension, heart disease, or sleep apnea — you likely meet current FDA eligibility criteria.
- Check manufacturer assistance programs. Novo Nordisk and Eli Lilly (LillyDirect) offer patient assistance programs and direct self-pay pricing for uninsured patients.
- Verify your Medicaid coverage specifically. Coverage varies by state and by clinical indication. If you have type 2 diabetes, your coverage is more likely than if the indication is weight loss only. Ask your pharmacist to run the claim before assuming it is denied.
- Appeal insurance denials. Denials are routinely overturned on appeal when properly documented. Ask your physician to write a letter of medical necessity citing your qualifying conditions and the clinical guidelines that support the prescription.
- Find a Federally Qualified Health Center. FQHCs serve patients regardless of ability to pay and are increasingly prescribing GLP-1 drugs. Find yours at findahealthcenter.hrsa.gov.
- Hold legislators accountable. Contact your state representative and your Congressional representative. Ask them specifically where they stand on Medicaid coverage for GLP-1 medications for weight loss.
GLP-1 drugs are the most powerful tool in metabolic medicine in a generation. They are cutting obesity rates, preventing heart attacks, protecting kidneys, and extending lives. The clinical evidence is settled.
Black Americans carry the highest rates of every condition these drugs treat. Consequently, we are the patients who stand to benefit most. And yet, we are being prescribed them at the lowest rates — locked out by a combination of price barriers, insurance exclusions, primary care deserts, and the same implicit bias that has characterized American medicine’s relationship with Black patients for two centuries.
The data makes the case. The system is making a choice. And the people paying the price — with their health, with their years, with their lives — are the same people who have always paid the price when American medicine decides some bodies matter less than others.
That is not complexity. That is a choice. And choices, unlike biology, can be changed.
Jeff Thomas — Publisher & Editor, Black Source Media
Jeff Thomas is the publisher of Black Source Media and a New Orleans entrepreneur with thirty years of experience in technology, contracting, and community advocacy. His health reporting is data-driven, builds to a verdict, and pulls no punches. He writes Sundays for Black Source Media.